IRESSA is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK (see Precautions).
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
